<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112520">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01771666</url>
  </required_header>
  <id_info>
    <org_study_id>BRS0022</org_study_id>
    <secondary_id>SU-06122012-10130</secondary_id>
    <secondary_id>21030</secondary_id>
    <nct_id>NCT01771666</nct_id>
  </id_info>
  <brief_title>Pilot Indocyanine Green™ Imaging for Mapping of Arm Draining Lymphatics &amp; Nodes in Breast Cancer</brief_title>
  <official_title>A Pilot Study to Assess the Utility of Indocyanine Green™ (IC-GREEN™) SPY Imaging in the Mapping of Arm Draining Lymphatics and Nodes During Sentinel Node Resection With or Without Axillary Dissection in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine concordance between isosulfan blue (ISB) and indocyanine green (IC-GREEN™) in
      the identification of lymphatics and arm-draining nodes during nodal staging procedures in
      breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percent of patients with blue and fluorescent lymphatics and nodes</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of blue sentinel nodes or with ex-vivo fluorescence</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ISB and IC-Green Dye</arm_group_label>
    <description>The dose of ISB dye is 3 to 5 mL and IC-Green™ will be started at 1 mg/mL.  If fluorescence is not detected with this dose, then it will be increased by 50%. A gamma probe [Neoprobe 2010] will be used to localize the sentinel lymph nodes in the axilla.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>(IC-GREEN™) SPY Elite® Imaging</intervention_name>
    <arm_group_label>ISB and IC-Green Dye</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women undergoing sentinel node resection with or without axillary lymph node dissection
        (ALND) for breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and the willingness to sign a written informed consent
             document.

          -  Signed written informed consent.

          -  Women undergoing sentinel lymph node biopsy.

          -  Women with breast cancer with known or suspected lymph node involvement.

          -  Women undergoing sentinel node identification and completion axillary lymph node
             dissection.

          -  Women of 18 years of age or older.

          -  Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2.

          -  Complete Blood Count (CBC) and basic Metabolic Panel within 6 months

        Exclusion Criteria:

          -  History of liver or kidney failure will not be eligible.

          -  Allergies to iodine containing products will not be eligible.

          -  Women who are pregnant will not be eligible.

          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Wapnir</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shannon Meyer</last_name>
    <phone>6507241953</phone>
    <email>smeyer27@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Meyer</last_name>
      <phone>650-724-1953</phone>
      <email>smeyer27@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Irene Wapnir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 25, 2013</lastchanged_date>
  <firstreceived_date>January 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
